Page 14 - 2022-36-中国全科医学
P. 14

http://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn  ·4489·


           余叶蓉负责文章的可行性分析和质量控制及审校、                                   Compassionate Use Programme in France［J］. Eur J Endocrinol，
           监督管理。                                                    2018，178（5）：447-458. DOI：10.1530/EJE-17-0886.
                                                               ［15］OLLIVIER M，HAISSAGUERRE M，FERRIERE A，et al.
               本文无利益冲突。
                                                                    Should we avoid using ketoconazole in patients with severe Cushing's
           参考文献                                                     syndrome and increased levels of liver enzymes? ［J］. Eur J
           ［1］FLESERIU M，AUCHUS R，BANCOS I，et al. Consensus on      Endocrinol，2018，179（5）：L1-L2. DOI：10.1530/EJE-18-
               diagnosis and management of Cushing's disease：a guideline   0694.
               update［J］. Lancet Diabetes Endocrinol，2021，9（12）： 847-  ［16］FEELDERS R A，HOFLAND L J，DE HERDER W W. Medical
               875. DOI：10.1016/S2213-8587(21)00235-7.              treatment of Cushing's syndrome：adrenal-blocking drugs and
           ［2］NIEMAN L K，BILLER B M K，FINDLING J W，et al. The       ketaconazole［J］. Neuroendocrinology，2010，92（Suppl 1）：
               diagnosis of Cushing's syndrome：an endocrine society clinical   111-115. DOI：10.1159/000314292.
               practice guideline［J］. J Clin Endocrinol Metab，2008，93（5）：  ［17］DANIEL E，AYLWIN S，MUSTAFA O，et al. Effectiveness
               1526-1540. DOI：10.1210/jc.2008-0125.                 of metyrapone in treating Cushing's syndrome：a retrospective
           ［3］NIEMAN L K，BILLER B M，FINDLING J W，et al. Treatment   multicenter study in 195 patients［J］. J Clin Endocrinol Metab，
               of Cushing's syndrome：an endocrine society clinical practice   2015，100（11）：4146-4154. DOI：10.1210/jc.2015-2616.
               guideline［J］. J Clin Endocrinol Metab，2015，100（8）：2807-  ［18］SIMÕES  CORRÊA  GALENDI  J，CORREA  NETO  A  N  S，
               2831. DOI：10.1210/jc.2015-1818.                      DEMETRES M，et al. Effectiveness of medical treatment of
           ［4］BILLER B M，GROSSMAN A B，STEWART P M，et al. Treatment   Cushing's disease：a systematic review and meta-analysis［J］.
               of adrenocorticotropin-dependent Cushing's syndrome：a consensus   Front Endocrinol （Lausanne），2021，12：732240. DOI：
               statement［J］. J Clin Endocrinol Metab，2008，93（7）：2454-  10.3389/fendo.2021.732240.
               2462. DOI：10.1210/jc.2007-2734.                 ［19］NIEMAN L K，BOSCARO M，SCARONI C M，et al. Metyrapone
           ［5］CAPATINA C，HINOJOSA-AMAYA J M，POIANA C，et al.         treatment in endogenous Cushing's syndrome：results at week
               Management of patients with persistent or recurrent Cushing's disease   12 from PROMPT，a prospective international multicenter，
               after initial pituitary surgery［J］. Expert Rev Endocrinol Metab，  open-label，phase Ⅲ / Ⅳ study［J］. J Endocr Soc，2021，5
               2020，15（5）：321-339. DOI：10.1080/17446651.2020.1802243.  （Supplement_1）：A515. DOI：10.1210/jendso/bvab048.1053.
           ［6］PIVONELLO R，DE LEO M，COZZOLINO A，et al. The treatment   ［20］BERTAGNA X，PIVONELLO R，FLESERIU M，et al. LCI699，
               of Cushing's disease［J］. Endocr Rev，2015，36（4）：385-486.   a potent 11β-hydroxylase inhibitor，normalizes urinary cortisol in
               DOI：10.1210/er.2013-1048.                            patients with Cushing's disease：results from a multicenter，proof-
           ［7］CUEVAS-RAMOS D，FLESERIU M. Treatment of Cushing's     of-concept study［J］. J Clin Endocrinol Metab，2014，99（4）：
               disease：a mechanistic update［J］. J Endocrinol，2014，223（2）：  1375-1383. DOI：10.1210/jc.2013-2117.
               R19-R39. DOI：10.1530/JOE-14-0300.               ［21］PIVONELLO R，FLESERIU M，NEWELL-PRICE J，et al.
           ［8］PIVONELLO R，FERRIGNO R，DE MARTINO M C，et al.          Efficacy and safety of osilodrostat in patients with Cushing's disease
               Medical treatment of Cushing's disease：an overview of the current   （LINC 3）：a multicentre phase Ⅲ study with a double-blind，
               and recent clinical trials［J］. Front Endocrinol （Lausanne），  randomised withdrawal phase［J］. Lancet Diabetes Endocrinol，
               2020，11：648. DOI：10.3389/fendo.2020.00648.           2020，8（9）：748-761. DOI：10.1016/S2213-8587(20)30240-0.
           ［9］VARLAMOV E V，HAN A J，FLESERIU M. Updates in adrenal   ［22］GADELHA M，BEX M，FEELDERS R A，et al. Osilodrostat is an
               steroidogenesis inhibitors for Cushing's syndrome—a practical   effective and well-tolerated treatment for Cushing's disease （CD）：
               guide［J］. Best Pract Res Clin Endocrinol Metab，2021，35（1）：  results from a phase Ⅲ study with an upfront，randomized，double-
               101490. DOI：10.1016/j.beem.2021.101490.              blind，placebo-controlled phase （LINC 4）［J］. J Endocr Soc，
           ［10］CASTINETTI F，GUIGNAT L，GIRAUD P，et al. Ketoconazole in
                                                                    2021，5（Supplement_1）：A516-517. DOI：10.1210/jendso/
               Cushing's disease：is it worth a try? ［J］. J Clin Endocrinol Metab，  bvab048.1055.
               2014，99（5）：1623-1630. DOI：10.1210/jc.2013-3628.
                                                               ［23］TRITOS N A，BILLER B M K. Advances in the medical treatment
           ［11］WINQUIST E W，LASKEY J，CRUMP M，et al. Ketoconazole in   of cushing disease［J］. Endocrinol Metab Clin North Am，2020，
               the management of paraneoplastic Cushing's syndrome secondary to
                                                                    49（3）：401-412. DOI：10.1016/j.ecl.2020.05.003.
               ectopic adrenocorticotropin production［J］. J Clin Oncol，1995，
                                                               ［24］HINOJOSA-AMAYA J M，CUEVAS-RAMOS D，FLESERIU M.
               13（1）：157-164. DOI：10.1200/JCO.1995.13.1.157.
                                                                    Medical management of Cushing's syndrome：current and emerging
           ［12］MARQUES J V O，BOGUSZEWSKI C L. Medical therapy in severe
                                                                    treatments［J］. Drugs，2019，79（9）：935-956. DOI：
               hypercortisolism［J］. Best Pract Res Clin Endocrinol Metab，
                                                                    10.1007/s40265-019-01128-7.
               2021，35（2）：101487. DOI：10.1016/j.beem.2021.101487.
                                                               ［25］CARROLL T B，PEPPARD W J，HERRMANN D J，et al.
           ［13］SONINO N，BOSCARO M，PAOLETTA A，et al. Ketoconazole
                                                                    Continuous etomidate infusion for the management of severe cushing
               treatment in Cushing's syndrome：experience in 34 patients［J］.
                                                                    syndrome：validation of a standard protocol［J］. J Endocr Soc，
               Clin Endocrinol （Oxf），1991，35（4）：347-352. DOI：
                                                                    2019，3（1）：1-12. DOI：10.1210/js.2018-00269.
               10.1111/j.1365-2265.1991.tb03547.x.
                                                               ［26］SCHULTE H M，BENKER G，REINWEIN D，et al. Infusion
           ［14］YOUNG  J，BERTHERAT  J，VANTYGHEM  M  C，et  al.
                                                                    of low dose etomidate：correction of hypercortisolemia in patients
               Hepatic safety of ketoconazole in Cushing's syndrome：results of a
                                                                    with Cushing's syndrome and dose-response relationship in normal
   9   10   11   12   13   14   15   16   17   18   19